Autoimmunity, Polyclonal B-Cell Activation and Infection
- 1 February 1992
- journal article
- research article
- Published by SAGE Publications in Lupus
- Vol. 1 (2) , 63-74
- https://doi.org/10.1177/096120339200100203
Abstract
It is widely believed that autoimmunity is an integral part of the immune system, and that genetic, immunologic, hormonal, environmental and other factors contribute to the pathogenesis of autoimmune disease. Thus, autoimmune disease may represent an abnormal expression of immune functions instead of loss of tolerance to self, and it can be organ specific or systemic in its manifestations. We review the various factors that contribute to the development of autoimmune disease; we also review the mechanisms of polyclonal B-cell activation, with emphasis on the role of infectious agents. We consider systemic lupus erythematosus in humans and in experimental animals as prototypic autoimmune disease, and we summarize data to indicate that polyclonal B-cell activation is central to the pathogenesis of systemic autoimmune disease. The effect of polyclonal B-cell activation, brought about by injections of a B-cell activator - lipopolysaccharide from Gram-negative bacteria—is sufficient to cause autoimmune disease in an immunologically normal host. In fact, autoimmune disease can be arrested if excessive polyclonal B-cell activation is suppressed; alternatively, autoimmune disease can be exacerbated if polyclonal B-cell activation is enhanced. We explore the mechanism of tissue injury when autoimmune disease is induced or exacerbated, and we consider the pathogenic roles of autoantibodies, immune complexes, complement, the blood cell carrier system, and the mononuclear phagocyte system. Although polyclonal B-cell activation may be the mechanism whereby various factors can cause or exacerbate systemic autoimmune disease, polyclonal B-cell activation may cause autoimmune disease on its own.Keywords
This publication has 84 references indexed in Scilit:
- The mosaic of autoimmunityPublished by Elsevier ,2003
- Bacterial lipopolysaccharide enhances deposition of immune complexes and exacerbates nephritis in BXSB lupus-prone miceClinical and Experimental Immunology, 1991
- Central MHC genes, IgA deficiency and autoimmune diseaseImmunology Today, 1990
- Repeated exposure to bacterial lipopolysaccharide interferes with disposal of pathogenic immune complexes in miceClinical and Experimental Immunology, 1990
- Autoimmunity and sex revisitedClinical Immunology and Immunopathology, 1989
- Paf-acether (platelet-activating factor) and interleukin-1-like cytokine production by lipopolysaccharide-stimulated glomeruliClinical Immunology and Immunopathology, 1988
- Anti-RNA polymerase I antibodies in sera of MRL lpr/lpr and MRL +/+ autoimmune mice. Correlation of antibody production with delayed onset of lupus-like disease in MRL +/+ mice.The Journal of Experimental Medicine, 1985
- Factors influencing the binding of large immune complexes to the primate erythrocyte CR1 receptorClinical Immunology and Immunopathology, 1984
- Mode of Inheritance of Decreased C3b Receptors on Erythrocytes of Patients with Systemic Lupus ErythematosusNew England Journal of Medicine, 1982
- Defective Reticuloendothelial System Fc-Receptor Function in Systemic Lupus ErythematosusNew England Journal of Medicine, 1979